Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall bought 137,100 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $7.29 per share, with a total value of $999,459.00. Following the completion of the transaction, the chief executive officer now owns 806,736 shares in the company, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Immunome Stock Up 2.0 %
NASDAQ IMNM opened at $7.09 on Thursday. Immunome, Inc. has a 12-month low of $6.94 and a 12-month high of $26.70. The firm has a market cap of $616.48 million, a P/E ratio of -0.87 and a beta of 1.93. The company's 50 day moving average is $9.61 and its 200-day moving average is $11.41.
Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. Equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.
Analyst Ratings Changes
Several research firms recently weighed in on IMNM. Guggenheim reduced their price target on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. Wedbush reissued an "outperform" rating and set a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Stephens reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Lifesci Capital started coverage on Immunome in a report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $25.50.
Read Our Latest Research Report on IMNM
Institutional Trading of Immunome
A number of hedge funds and other institutional investors have recently bought and sold shares of IMNM. BNP Paribas Financial Markets purchased a new position in shares of Immunome during the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS purchased a new position in shares of Immunome during the fourth quarter worth about $75,000. AlphaQuest LLC grew its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Immunome during the fourth quarter valued at approximately $95,000. Institutional investors own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
